The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

NCT07020260 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
18
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Princess Maxima Center for Pediatric Oncology

Collaborators